These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20648509)

  • 21. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD; Huang L
    Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles.
    Vandenbroucke RE; Lentacker I; Demeester J; De Smedt SC; Sanders NN
    J Control Release; 2008 Mar; 126(3):265-73. PubMed ID: 18237813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different mechanisms for nanoparticle formation between pDNA and siRNA using polyrotaxane as the polycation.
    Yamada Y; Hashida M; Nomura T; Harashima H; Yamasaki Y; Kataoka K; Yamashita A; Katoono R; Yui N
    Chemphyschem; 2012 Apr; 13(5):1161-5. PubMed ID: 22383277
    [No Abstract]   [Full Text] [Related]  

  • 24. Self-assembling polyethylenimine derivatives mediate efficient siRNA delivery in mammalian cells.
    Creusat G; Zuber G
    Chembiochem; 2008 Nov; 9(17):2787-9. PubMed ID: 18972467
    [No Abstract]   [Full Text] [Related]  

  • 25. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
    Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
    J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
    Ulbrich K; Hekmatara T; Herbert E; Kreuter J
    Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles.
    Carmona S; Jorgensen MR; Kolli S; Crowther C; Salazar FH; Marion PL; Fujino M; Natori Y; Thanou M; Arbuthnot P; Miller AD
    Mol Pharm; 2009; 6(3):706-17. PubMed ID: 19159285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers.
    Lee SH; Bae KH; Kim SH; Lee KR; Park TG
    Int J Pharm; 2008 Nov; 364(1):94-101. PubMed ID: 18723087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydrodynamic delivery protocols.
    Rychahou PG; Evers BM
    Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles.
    Elfakess R; Peer D
    IDrugs; 2010 Sep; 13(9):626-31. PubMed ID: 20799145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of AZT-based cationic lipids and in vitro evaluation of siRNA delivery.
    Park SM; Woo J; Jeon E; Kim BH
    Chem Commun (Camb); 2010 Mar; 46(9):1523-5. PubMed ID: 20162169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous short-interfering RNA therapy.
    Geusens B; Sanders N; Prow T; Van Gele M; Lambert J
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1333-49. PubMed ID: 19941411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery.
    Kataoka K; Itaka K; Nishiyama N; Yamasaki Y; Oishi M; Nagasaki Y
    Nucleic Acids Symp Ser (Oxf); 2005; (49):17-8. PubMed ID: 17150611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA).
    Tsutsumi T; Hirayama F; Uekama K; Arima H
    J Control Release; 2007 Jun; 119(3):349-59. PubMed ID: 17477999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the delivery of small interfering RNAs into mammalian cells.
    Sioud M
    Expert Opin Drug Deliv; 2005 Jul; 2(4):639-51. PubMed ID: 16296791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
    Wang XL; Xu R; Lu ZR
    J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.